Home / Asia-Pacific / Singapore / Life Sciences & Healthcare

Life Sciences & Healthcare

As part of a global team with over 480 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences business. We work with and have established long-term relationships with the top 100 lifesciences companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.


Feed

22/11/2022
Glob­al Life Sci­ences & Health­care For­um 2022: Life Sci­ences are reap­ing...
Di­git­al trans­form­a­tion in life sci­ences is cre­at­ing op­por­tun­it­ies to counter health­care’s most in­tract­able prob­lems from treat­ing rare dis­eases to ac­cel­er­at­ing dia­gnostics and re­du­cing treat­ment back­logs...
09/11/2022
Glob­al Life Sci­ences & Health­care For­um 2022: The Life Sci­ences sec­tor...
The open­ing of COP27 has brought an in­tense glob­al fo­cus on cli­mate change and the tower­ing de­mands needed to reach car­bon net zero and to pro­tect the en­vir­on­ment. United Na­tions Gen­er­al Sec­ret­ary Ant­o­nio...
02/11/2022
Glob­al Life Sci­ences & Health­care For­um 2022: The leg­al sec­tor has a key...
The United Na­tions has pledged to use its pur­chas­ing fire­power to ac­cel­er­ate sus­tain­ab­il­ity along the health­care sup­ply chan­nel and called on the leg­al sec­tor to sup­port its ef­forts. Law­yers are crit­ic­al...
02/11/2022
APAC IP Up­date – Au­tumn 2022
China CNIPA re­leases China Pat­ent Sur­vey Re­port 2021 In Ju­ly 2022, the China Na­tion­al In­tel­lec­tu­al Prop­erty Ad­min­is­tratiion (CNIPA) re­leased the China Pat­ent Sur­vey Re­port 2021. The data in the re­port...
07/06/2022
Trade secret laws and reg­u­la­tions in Singa­pore
Gen­er­al 1. Has the Dir­ect­ive (EU) 2016/943 of the European Par­lia­ment and of the Coun­cil of 8 June 2016 on the pro­tec­tion of un­dis­closed know-how and busi­ness in­form­a­tion (trade secrets) against their...
Comparable
07/06/2022
Ad­verse ef­fects of drugs and vac­cines in Singa­pore
1. Drug ad­verse ef­fects: kinds of re­spons­ib­il­ity 1.1 Which are the main kinds of re­spons­ib­il­ity (con­trac­tu­al, in tort, crim­in­al) of the fol­low­ing sub­jects with re­spect to ad­verse drugs re­ac­tions? For...
Comparable
01/06/2022
CMS Next
What’s next? In a world of ever-ac­cel­er­at­ing change, stay­ing ahead of the curve and know­ing what’s next for your busi­ness or sec­tor is es­sen­tial.At CMS, we see ourselves not only as your leg­al ad­visers but also as your busi­ness part­ners. We work to­geth­er with you to not only re­solve cur­rent is­sues but to an­ti­cip­ate fu­ture chal­lenges and in­nov­ate to meet them.With our latest pub­lic­a­tion, CMS Next, our ex­perts will reg­u­larly of­fer you in­sights in­to and fresh per­spect­ives on a range of is­sues that busi­nesses have to deal with – from ESG agen­das to re­struc­tur­ing after the pan­dem­ic or fa­cing the di­git­al trans­form­a­tion. We will also share with you more about the work that we are do­ing for our cli­ents, help­ing them in­nov­ate, grow and mit­ig­ate risk.To be able to provide you with the best sup­port, we im­merse ourselves in your world to un­der­stand your leg­al needs and chal­lenges. However, it is equally im­port­ant that you know who we are and how we can work with you. So, we in­vite you to meet our ex­perts and catch a glimpse of what is hap­pen­ing in­side CMS.En­joy read­ing this pub­lic­a­tion, which we will up­date reg­u­larly with new con­tent.CMS Ex­ec­ut­ive Team
16/03/2022
APAC IP Up­date – Winter 2021-2022
China CNIPA re­leases the Amended Meas­ures for Re­gis­tra­tion of Pledge of Pat­ent Rights On 16 Novem­ber 2021, the China Na­tion­al In­tel­lec­tu­al Prop­erty Ad­min­is­tra­tion (CNIPA) re­leased the amended “Meas­ures...
21/12/2021
APAC IP Up­date – Winter 2021
China China en­cour­ages IP dis­putes me­di­ation On 22 Oc­to­ber 2021, the China Na­tion­al In­tel­lec­tu­al Prop­erty Ad­min­is­tra­tion (CNIPA) and the Min­istry of Justice jointly is­sued “the Opin­ions on Strength­en­ing...
26/11/2021
COV­ID-19 vac­cin­a­tion and test­ing in Singa­pore - em­ploy­ment law per­spect­ive
Vac­cin­a­tion 1. What op­tions does the em­ploy­er have to en­cour­age em­ploy­ees to be vac­cin­ated? Can the em­ploy­er provide a fin­an­cial in­cent­ive to em­ploy­ees? All em­ploy­ers are en­cour­aged to ad­opt the “Vac­cine...
Comparable
24/11/2021
On the Pulse
Wel­come to CMS ‘On the Pulse’ video/pod­cast series for all Life Sci­ences & Health­care pro­fes­sion­als – leg­al, com­pli­ance, reg­u­lat­ory
08/11/2021
ESO­Ps and Bal­an­cing Key Stake­hold­er In­terests
This art­icle is pro­duced by CMS Hol­born Asia, a Form­al Law Al­li­ance between CMS Singa­pore and Hol­born Law LLC. As the South East Asi­an start-up and emer­ging com­pany scene con­tin­ues to rap­idly ex­pand and...